Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.
Non-small Cell Lung Cancer
DRUG: Erlotinib|DRUG: Chemotherapy
Progression-free survival of the whole study population and in the strata 1-2, An expected average of 36 weeks after last subject enrolled into our study
Overall Survival, An expected average of 52 weeks after last subject enrolled into our study|Overall Response Rate, An expected average of 36 weeks after last subject enrolled into our study|Rate of non-progression at 9 and 18 weeks, 18 weeks after date of randomization of a last patient|Safety and toxicity, Number of Participants with Adverse Events as a Measure of Safety and Tolerability, An expected average of 52 weeks after last subject enrolled into our study
A Phase II randomised, multicenter study to assess the efficacy and safety of continuing erlotinib in addition to chemotherapy versus chemotherapy alone in patients who have EGFR mutant or EGFR TKI responsive NSCLC and have progressed on EGFR TKI.